The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hospital Acquired Infections Drugs Market Research Report 2025
Synopsis
A hospital-acquired infection (HAI) is an infection whose development is favoured by a hospital environment, such as one acquired by a patient during a hospital visit. The most common types are bloodstream infection (BSI), pneumonia (eg, ventilator-associated pneumonia [VAP]), urinary tract infection (UTI), and surgical site infection (SSI). Antifungal therapy (eg, fluconazole, caspofungin, voriconazole, amphotericin B) in some cases are added to empiric antibiotic coverage. Antiviral therapy (eg, ganciclovir, acyclovir) can be used in the treatment of suspected disseminated viral infections.
The global Hospital Acquired Infections Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hospital Acquired Infections Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital Acquired Infections Drugs.
Report Scope
The Hospital Acquired Infections Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hospital Acquired Infections Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hospital Acquired Infections Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Pfizer
Bayer
GlaxoSmithKline
Daiichi Sankyo
AbbVie
Abbott Laboratories
Roche
Jiangsu Hengrui Medicine
Eli Lilly
Segment by Type
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Segment by Application
Urinary Tract Infections
Ventilator-associated Pneumonia
Surgical Site Infections
Bloodstream Infections
Other Hospital Infections
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hospital Acquired Infections Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A hospital-acquired infection (HAI) is an infection whose development is favoured by a hospital environment, such as one acquired by a patient during a hospital visit. The most common types are bloodstream infection (BSI), pneumonia (eg, ventilator-associated pneumonia [VAP]), urinary tract infection (UTI), and surgical site infection (SSI). Antifungal therapy (eg, fluconazole, caspofungin, voriconazole, amphotericin B) in some cases are added to empiric antibiotic coverage. Antiviral therapy (eg, ganciclovir, acyclovir) can be used in the treatment of suspected disseminated viral infections.
The global Hospital Acquired Infections Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hospital Acquired Infections Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital Acquired Infections Drugs.
Report Scope
The Hospital Acquired Infections Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hospital Acquired Infections Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hospital Acquired Infections Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Pfizer
Bayer
GlaxoSmithKline
Daiichi Sankyo
AbbVie
Abbott Laboratories
Roche
Jiangsu Hengrui Medicine
Eli Lilly
Segment by Type
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Segment by Application
Urinary Tract Infections
Ventilator-associated Pneumonia
Surgical Site Infections
Bloodstream Infections
Other Hospital Infections
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hospital Acquired Infections Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hospital Acquired Infections Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antibacterial Drugs
1.2.3 Antiviral Drugs
1.2.4 Antifungal Drugs
1.3 Market by Application
1.3.1 Global Hospital Acquired Infections Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Urinary Tract Infections
1.3.3 Ventilator-associated Pneumonia
1.3.4 Surgical Site Infections
1.3.5 Bloodstream Infections
1.3.6 Other Hospital Infections
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hospital Acquired Infections Drugs Market Perspective (2019-2030)
2.2 Hospital Acquired Infections Drugs Growth Trends by Region
2.2.1 Global Hospital Acquired Infections Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hospital Acquired Infections Drugs Historic Market Size by Region (2019-2024)
2.2.3 Hospital Acquired Infections Drugs Forecasted Market Size by Region (2025-2030)
2.3 Hospital Acquired Infections Drugs Market Dynamics
2.3.1 Hospital Acquired Infections Drugs Industry Trends
2.3.2 Hospital Acquired Infections Drugs Market Drivers
2.3.3 Hospital Acquired Infections Drugs Market Challenges
2.3.4 Hospital Acquired Infections Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hospital Acquired Infections Drugs Players by Revenue
3.1.1 Global Top Hospital Acquired Infections Drugs Players by Revenue (2019-2024)
3.1.2 Global Hospital Acquired Infections Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Hospital Acquired Infections Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hospital Acquired Infections Drugs Revenue
3.4 Global Hospital Acquired Infections Drugs Market Concentration Ratio
3.4.1 Global Hospital Acquired Infections Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hospital Acquired Infections Drugs Revenue in 2023
3.5 Hospital Acquired Infections Drugs Key Players Head office and Area Served
3.6 Key Players Hospital Acquired Infections Drugs Product Solution and Service
3.7 Date of Enter into Hospital Acquired Infections Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hospital Acquired Infections Drugs Breakdown Data by Type
4.1 Global Hospital Acquired Infections Drugs Historic Market Size by Type (2019-2024)
4.2 Global Hospital Acquired Infections Drugs Forecasted Market Size by Type (2025-2030)
5 Hospital Acquired Infections Drugs Breakdown Data by Application
5.1 Global Hospital Acquired Infections Drugs Historic Market Size by Application (2019-2024)
5.2 Global Hospital Acquired Infections Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hospital Acquired Infections Drugs Market Size (2019-2030)
6.2 North America Hospital Acquired Infections Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hospital Acquired Infections Drugs Market Size by Country (2019-2024)
6.4 North America Hospital Acquired Infections Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hospital Acquired Infections Drugs Market Size (2019-2030)
7.2 Europe Hospital Acquired Infections Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hospital Acquired Infections Drugs Market Size by Country (2019-2024)
7.4 Europe Hospital Acquired Infections Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hospital Acquired Infections Drugs Market Size (2019-2030)
8.2 Asia-Pacific Hospital Acquired Infections Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hospital Acquired Infections Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Hospital Acquired Infections Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hospital Acquired Infections Drugs Market Size (2019-2030)
9.2 Latin America Hospital Acquired Infections Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hospital Acquired Infections Drugs Market Size by Country (2019-2024)
9.4 Latin America Hospital Acquired Infections Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hospital Acquired Infections Drugs Market Size (2019-2030)
10.2 Middle East & Africa Hospital Acquired Infections Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hospital Acquired Infections Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Hospital Acquired Infections Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Hospital Acquired Infections Drugs Introduction
11.1.4 Merck Revenue in Hospital Acquired Infections Drugs Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Hospital Acquired Infections Drugs Introduction
11.2.4 Pfizer Revenue in Hospital Acquired Infections Drugs Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Hospital Acquired Infections Drugs Introduction
11.3.4 Bayer Revenue in Hospital Acquired Infections Drugs Business (2019-2024)
11.3.5 Bayer Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Hospital Acquired Infections Drugs Introduction
11.4.4 GlaxoSmithKline Revenue in Hospital Acquired Infections Drugs Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Detail
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Hospital Acquired Infections Drugs Introduction
11.5.4 Daiichi Sankyo Revenue in Hospital Acquired Infections Drugs Business (2019-2024)
11.5.5 Daiichi Sankyo Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Detail
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Hospital Acquired Infections Drugs Introduction
11.6.4 AbbVie Revenue in Hospital Acquired Infections Drugs Business (2019-2024)
11.6.5 AbbVie Recent Development
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Company Detail
11.7.2 Abbott Laboratories Business Overview
11.7.3 Abbott Laboratories Hospital Acquired Infections Drugs Introduction
11.7.4 Abbott Laboratories Revenue in Hospital Acquired Infections Drugs Business (2019-2024)
11.7.5 Abbott Laboratories Recent Development
11.8 Roche
11.8.1 Roche Company Detail
11.8.2 Roche Business Overview
11.8.3 Roche Hospital Acquired Infections Drugs Introduction
11.8.4 Roche Revenue in Hospital Acquired Infections Drugs Business (2019-2024)
11.8.5 Roche Recent Development
11.9 Jiangsu Hengrui Medicine
11.9.1 Jiangsu Hengrui Medicine Company Detail
11.9.2 Jiangsu Hengrui Medicine Business Overview
11.9.3 Jiangsu Hengrui Medicine Hospital Acquired Infections Drugs Introduction
11.9.4 Jiangsu Hengrui Medicine Revenue in Hospital Acquired Infections Drugs Business (2019-2024)
11.9.5 Jiangsu Hengrui Medicine Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Hospital Acquired Infections Drugs Introduction
11.10.4 Eli Lilly Revenue in Hospital Acquired Infections Drugs Business (2019-2024)
11.10.5 Eli Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Hospital Acquired Infections Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Antibacterial Drugs
Table 3. Key Players of Antiviral Drugs
Table 4. Key Players of Antifungal Drugs
Table 5. Global Hospital Acquired Infections Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Hospital Acquired Infections Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Hospital Acquired Infections Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Hospital Acquired Infections Drugs Market Share by Region (2019-2024)
Table 9. Global Hospital Acquired Infections Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Hospital Acquired Infections Drugs Market Share by Region (2025-2030)
Table 11. Hospital Acquired Infections Drugs Market Trends
Table 12. Hospital Acquired Infections Drugs Market Drivers
Table 13. Hospital Acquired Infections Drugs Market Challenges
Table 14. Hospital Acquired Infections Drugs Market Restraints
Table 15. Global Hospital Acquired Infections Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Hospital Acquired Infections Drugs Market Share by Players (2019-2024)
Table 17. Global Top Hospital Acquired Infections Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hospital Acquired Infections Drugs as of 2023)
Table 18. Ranking of Global Top Hospital Acquired Infections Drugs Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Hospital Acquired Infections Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Hospital Acquired Infections Drugs Product Solution and Service
Table 22. Date of Enter into Hospital Acquired Infections Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Hospital Acquired Infections Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Hospital Acquired Infections Drugs Revenue Market Share by Type (2019-2024)
Table 26. Global Hospital Acquired Infections Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Hospital Acquired Infections Drugs Revenue Market Share by Type (2025-2030)
Table 28. Global Hospital Acquired Infections Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Hospital Acquired Infections Drugs Revenue Market Share by Application (2019-2024)
Table 30. Global Hospital Acquired Infections Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Hospital Acquired Infections Drugs Revenue Market Share by Application (2025-2030)
Table 32. North America Hospital Acquired Infections Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Hospital Acquired Infections Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Hospital Acquired Infections Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Hospital Acquired Infections Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Hospital Acquired Infections Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Hospital Acquired Infections Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Hospital Acquired Infections Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Hospital Acquired Infections Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Hospital Acquired Infections Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Hospital Acquired Infections Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Hospital Acquired Infections Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Hospital Acquired Infections Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Hospital Acquired Infections Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Hospital Acquired Infections Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Hospital Acquired Infections Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Merck Company Detail
Table 48. Merck Business Overview
Table 49. Merck Hospital Acquired Infections Drugs Product
Table 50. Merck Revenue in Hospital Acquired Infections Drugs Business (2019-2024) & (US$ Million)
Table 51. Merck Recent Development
Table 52. Pfizer Company Detail
Table 53. Pfizer Business Overview
Table 54. Pfizer Hospital Acquired Infections Drugs Product
Table 55. Pfizer Revenue in Hospital Acquired Infections Drugs Business (2019-2024) & (US$ Million)
Table 56. Pfizer Recent Development
Table 57. Bayer Company Detail
Table 58. Bayer Business Overview
Table 59. Bayer Hospital Acquired Infections Drugs Product
Table 60. Bayer Revenue in Hospital Acquired Infections Drugs Business (2019-2024) & (US$ Million)
Table 61. Bayer Recent Development
Table 62. GlaxoSmithKline Company Detail
Table 63. GlaxoSmithKline Business Overview
Table 64. GlaxoSmithKline Hospital Acquired Infections Drugs Product
Table 65. GlaxoSmithKline Revenue in Hospital Acquired Infections Drugs Business (2019-2024) & (US$ Million)
Table 66. GlaxoSmithKline Recent Development
Table 67. Daiichi Sankyo Company Detail
Table 68. Daiichi Sankyo Business Overview
Table 69. Daiichi Sankyo Hospital Acquired Infections Drugs Product
Table 70. Daiichi Sankyo Revenue in Hospital Acquired Infections Drugs Business (2019-2024) & (US$ Million)
Table 71. Daiichi Sankyo Recent Development
Table 72. AbbVie Company Detail
Table 73. AbbVie Business Overview
Table 74. AbbVie Hospital Acquired Infections Drugs Product
Table 75. AbbVie Revenue in Hospital Acquired Infections Drugs Business (2019-2024) & (US$ Million)
Table 76. AbbVie Recent Development
Table 77. Abbott Laboratories Company Detail
Table 78. Abbott Laboratories Business Overview
Table 79. Abbott Laboratories Hospital Acquired Infections Drugs Product
Table 80. Abbott Laboratories Revenue in Hospital Acquired Infections Drugs Business (2019-2024) & (US$ Million)
Table 81. Abbott Laboratories Recent Development
Table 82. Roche Company Detail
Table 83. Roche Business Overview
Table 84. Roche Hospital Acquired Infections Drugs Product
Table 85. Roche Revenue in Hospital Acquired Infections Drugs Business (2019-2024) & (US$ Million)
Table 86. Roche Recent Development
Table 87. Jiangsu Hengrui Medicine Company Detail
Table 88. Jiangsu Hengrui Medicine Business Overview
Table 89. Jiangsu Hengrui Medicine Hospital Acquired Infections Drugs Product
Table 90. Jiangsu Hengrui Medicine Revenue in Hospital Acquired Infections Drugs Business (2019-2024) & (US$ Million)
Table 91. Jiangsu Hengrui Medicine Recent Development
Table 92. Eli Lilly Company Detail
Table 93. Eli Lilly Business Overview
Table 94. Eli Lilly Hospital Acquired Infections Drugs Product
Table 95. Eli Lilly Revenue in Hospital Acquired Infections Drugs Business (2019-2024) & (US$ Million)
Table 96. Eli Lilly Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hospital Acquired Infections Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Hospital Acquired Infections Drugs Market Share by Type: 2023 VS 2030
Figure 3. Antibacterial Drugs Features
Figure 4. Antiviral Drugs Features
Figure 5. Antifungal Drugs Features
Figure 6. Global Hospital Acquired Infections Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Hospital Acquired Infections Drugs Market Share by Application: 2023 VS 2030
Figure 8. Urinary Tract Infections Case Studies
Figure 9. Ventilator-associated Pneumonia Case Studies
Figure 10. Surgical Site Infections Case Studies
Figure 11. Bloodstream Infections Case Studies
Figure 12. Other Hospital Infections Case Studies
Figure 13. Hospital Acquired Infections Drugs Report Years Considered
Figure 14. Global Hospital Acquired Infections Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Hospital Acquired Infections Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Hospital Acquired Infections Drugs Market Share by Region: 2023 VS 2030
Figure 17. Global Hospital Acquired Infections Drugs Market Share by Players in 2023
Figure 18. Global Top Hospital Acquired Infections Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hospital Acquired Infections Drugs as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Hospital Acquired Infections Drugs Revenue in 2023
Figure 20. North America Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Hospital Acquired Infections Drugs Market Share by Country (2019-2030)
Figure 22. United States Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Hospital Acquired Infections Drugs Market Share by Country (2019-2030)
Figure 26. Germany Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Hospital Acquired Infections Drugs Market Share by Region (2019-2030)
Figure 34. China Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Hospital Acquired Infections Drugs Market Share by Country (2019-2030)
Figure 42. Mexico Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Hospital Acquired Infections Drugs Market Share by Country (2019-2030)
Figure 46. Turkey Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Hospital Acquired Infections Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Merck Revenue Growth Rate in Hospital Acquired Infections Drugs Business (2019-2024)
Figure 49. Pfizer Revenue Growth Rate in Hospital Acquired Infections Drugs Business (2019-2024)
Figure 50. Bayer Revenue Growth Rate in Hospital Acquired Infections Drugs Business (2019-2024)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Hospital Acquired Infections Drugs Business (2019-2024)
Figure 52. Daiichi Sankyo Revenue Growth Rate in Hospital Acquired Infections Drugs Business (2019-2024)
Figure 53. AbbVie Revenue Growth Rate in Hospital Acquired Infections Drugs Business (2019-2024)
Figure 54. Abbott Laboratories Revenue Growth Rate in Hospital Acquired Infections Drugs Business (2019-2024)
Figure 55. Roche Revenue Growth Rate in Hospital Acquired Infections Drugs Business (2019-2024)
Figure 56. Jiangsu Hengrui Medicine Revenue Growth Rate in Hospital Acquired Infections Drugs Business (2019-2024)
Figure 57. Eli Lilly Revenue Growth Rate in Hospital Acquired Infections Drugs Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
